Page 16 - Observational Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Background: Fundamental to the success of clinical research that involves human participants is the quality of the data that is generated. To ensure data quality, clinical trials must comply with the Good Clinical Practice guideline which recommends data monitoring. To date, the guideline is broad, requires technology for enforcement, follows strict industry standards, mostly designed for drug-registration trials and based on informal consensus. It is also unknown what challenges clinical trials and researchers face in implementing data monitoring procedures. Thus, this study aimed to describe...

Press release content from PR Newswire. The AP news staff was not involved in its creation.

ABBVie today announced the presentation of new data on RINVOQ ® SKYRIZI ® and HUMIRA ® across multiple rheumatic diseases at the American College of Rheumatology's annual meeting to be held virtually Nov. 3-9 . A total of 38 abstracts, including two oral presentations and one plenary session presentation, will be presented from a broad range of studies in rheumatoid arthritis, psoriatic arthritis and ankylosing ...

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the presentation of new data on RINVOQ® (upadacitinib), SKYRIZI® (risankizumab) and HUMIRA® (adalimumab)...

Australia’s leading contract research organization focused on medicinal cannabis treatments 200 women to take part to monitor the safety & efficacy of medical cannabis as a management option for refractory chronic pain, a common endometriosis symptom. SYDNEY, NSW, AUSTRALIA, January 31, 2021 /EINPresswire.com/ — Applied Cannabis Research is pleased to announce Aruma Labs (Aruma) has joined Australia’s longest running observational study of medicinal cannabis products, the CA Clinics Observational Study (CACOS*), with a focus on collecting data from patients with endometriosis. Endometri...